Literature DB >> 9675462

Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors.

S L Ngui1, N J Andrews, G S Underhill, J Heptonstall, C G Teo.   

Abstract

A retrospective case-control study was conducted to determine why some infants born full-term without obstetric intervention to hepatitis B e antigen (HBeAg)-seropositive mothers become infected by hepatitis B virus (HBV) despite having received passive-active immunoprophylaxis. Cases and controls comprised 12 hepatitis B surface antigen (HBsAg)-seropositive infants and 22 HBsAg-seronegative infants, respectively. Infants infected by putative vaccine-escape mutants were excluded. Risk factors, after adjustment for the level of maternal viremia, were the following allelic base changes in maternal HBV:C158, A328, G365, and A479 (P = .017, .005, .003, and .005, respectively). High-level maternal viremia (i.e., > or = 10(8) genome equivalents/mL) was a significant factor only after adjustment for G365 (P = .027). HBV DNA sequences recovered from one of the cases, the case's mother, and three infected contacts all had the high-risk mutations. Specific allelic mutations in maternal HBV and level of maternal viremia are potential predictors of vertical breakthrough infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675462     DOI: 10.1086/514610

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice.

Authors:  C Quentin; C Arpin; V Dubois; C André; I Lagrange; I Fischer; J-P Brochet; F Grobost; J Jullin; B Dutilh; G Larribet; P Noury
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

Review 2.  Breastfeeding and chronic HBV infection: clinical and social implications.

Authors:  Mihaela Petrova; Victor Kamburov
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

3.  Immunoprophylaxis failure against vertical transmission of hepatitis B virus: what is the mechanism and do other factors also play a role?

Authors:  Jae Il Shin; Ran Namgung; Min Soo Park; Kook In Park; Chul Lee
Journal:  Eur J Pediatr       Date:  2007-05-22       Impact factor: 3.183

Review 4.  Pregnancy and liver disease.

Authors:  Grace L Su
Journal:  Curr Gastroenterol Rep       Date:  2008-02

Review 5.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

6.  A pregnant patient with a positive hepatitis B surface antigen.

Authors:  Arjmand Rasool Mufti; Nancy Reau
Journal:  Frontline Gastroenterol       Date:  2012-08-31

7.  Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants.

Authors:  Charles S Chasela; Athena P Kourtis; Patrick Wall; Jan Drobeniuc; Caroline C King; Hong Thai; Eyasu H Teshale; Mina Hosseinipour; Sascha Ellington; Mary B Codd; Denise J Jamieson; Rod Knight; Patricia Fitzpatrick; Saleem Kamili; Irving Hoffman; Dumbani Kayira; Noel Mumba; Deborah D Kamwendo; Francis Martinson; William Powderly; Chong-Gee Teo; Charles van der Horst
Journal:  J Hepatol       Date:  2013-11-06       Impact factor: 25.083

8.  Interruption of HBV intrauterine transmission: a clinical study.

Authors:  Xiao-Mao Li; Yue-Bo Yang; Hong-Ying Hou; Zhong-Jie Shi; Hui-Min Shen; Ben-Qi Teng; Ai-Min Li; Min-Feng Shi; Ling Zou
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 9.  Management of chronic hepatitis B in pregnancy.

Authors:  Guo-Rong Han; Chuan-Lu Xu; Wei Zhao; Yong-Feng Yang
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

10.  Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection.

Authors:  Xiao-Mao Li; Min-Feng Shi; Yue-Bo Yang; Zhong-Jie Shi; Hong-Ying Hou; Hui-Min Shen; Ben-Qi Teng
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.